Open Nav

Circle Pharma, Inc.

meet investors for series B, anticipated in late 2019

  • Date:Wednesday, October 17
  • Time:10:45 AM - 11:00 AM
  • Room:Elizabethan A
  • Location:2nd Floor
  • Session Type:Company Presentation
  • Presentation Type:Privately Funded Company
  • Company Description/Mission Statement:Circle is developing intrinsically cell-permeable macrocycles that can address both intra- and extra-cellular targets, and can be delivered by oral administration. Our macrocycle development platform is applicable across a wide range of serious diseases; we are initially focusing our internal development efforts on intracellular protein-protein interactions that are key drivers in molecularly defined cancers, including Cyclin A : cdk2, Cyclin E : cdk2, and beta-catenin. In addition, we have built a pilot physical library of cell permeable macrocycles. We are open to partnering opportunities to apply our macrocycle platform to targets that are challenging to address with conventional small molecule or biologics. We are currently raising a Series A-1 round of $10M to advance our pipeline to animal proof of concept ($5M received at the first closing) and anticipate raising a larger series B round in late 2019 to fund through to clinical data.
  • Company Website:www.circlepharma.com
  • Company HQ City:South San Francisco
  • Company HQ Country:United States
  • Company HQ State:California                  
  • CEO/Top Company Official:David J. Earp
  • Year Founded:2013
  • Main Therapeutic Focus:Oncology
  • Lead Product in Development :Cyclin A / cdk2 inhibitor
  • Development Phase of Primary Product:Pre-Clinical
  • Size of Last Investment Round:In process $10M series A-1 round, $5M in at first close
  • Total Amount Raised to Date, In All Rounds:$13.5M
Back